About the Authors

Knut M. Wittkowski

Affiliation The Rockefeller University, New York, New York, United States of America

Craig Leonardi

Affiliation St. Louis University Medical School, St. Louis University, St. Louis, Missouri, United States of America

Alice Gottlieb

Affiliation Tufts Medical Center, Tufts University, Boston, Massachusetts, United States of America

Alan Menter

Affiliation Baylor Institute of Research, Dermatology Research Center, Baylor University Medical Center, Baylor University, Dallas, Texas, United States of America

Gerald G. Krueger

Affiliation University of Utah, Salt Lake City, Utah, United States of America

Paul W. Tebbey

Affiliation International Psoriasis Council, Dallas, Texas, United States of America

Jennifer Belasco

jgk@rockefeller.edu (JGK); jbelasco@rockefeller.edu (JB)

Affiliation The Rockefeller University, New York, New York, United States of America

Razieh Soltani-Arabshahi

Affiliation University of Utah, Salt Lake City, Utah, United States of America

John Gray

Affiliation The Rockefeller University, New York, New York, United States of America

Liz Horn

Affiliation International Psoriasis Council, Dallas, Texas, United States of America

James G. Krueger

jgk@rockefeller.edu (JGK); jbelasco@rockefeller.edu (JB)

Affiliation The Rockefeller University, New York, New York, United States of America

for the International Psoriasis Council

Affiliation International Psoriasis Council, Dallas, Texas, United States of America

Competing Interests

Alan Menter, M.D. has the following conflicts of interest in the form of compensation: Abbott, Allergen, Amgen, Astellas, Asubio, Celgene, Centocor, DUSA, Eli Lilly, GAlderma, Genentech, Novartis, Novo Nordisk, Pfizer, Promius, Stiefel, Syntrix Biosystems, Warner Chilcott and Wyeth. This compensation is not for employment. Gerald G Krueger, M.D. has received fees as a consultant or advisory board member for Abbott, Almirall, Alza, Amgen, Anacor, Astellas, Barrier Therapeutics, Boehringer Ingleheim, Bristol Myers Squibb, Centocor, CombinatoRx, Exelixis, Genentech, Genzyme, Isis, L'Oreal, Lupin Limited, Magen Biosciencs, MedaCorp, Medicis, Novartis, Nova Nordisc, Schering Plough, Somagenics, theDerm.org, Synvista, Warner Chilcot, UCB, USANA Health Sciences and ZARS. Dr. Krueger owns equities and stock options in/from ZARS. In the last 24 months Dr. Krueger has received lecture fees from Abbott, AMgen, Astellas, Boehringer Ingleheim, Centocor, Connetics, National Psoriasis Foundation, The Foundation for Better Health Care and Warner Chilcott. Dr. Krueger has received partial stipend support for a clinical research fellowship from Abbott, Amgen and Centocor. Paul Tebbey, PhD. is employed by the International Psoriasis Council to provide scientific advice. James G. Krueger, M.D., Ph.D. has the following conflicts of interest: Abbott, Centocor, Janssen-Cilag, Pfizer, Merch, Avontec and Magen. They are all lecture honoraria or consulting and all less than $10,000 a year. The other authors have no conflicts of interest to report. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: KMW CL AG GGK LH JGK. Performed the experiments: CL AG AM GGK RS-A JG. Analyzed the data: KMW CL AG AM GGK PWT JB JG LH JGK. Contributed reagents/materials/analysis tools: KMW. Wrote the paper: KMW CL AG AM GGK PWT JB RS-A JG LH JGK.